The case for low-level BACE1 inhibition for the prevention of Alzheimer disease
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Alzheimer disease (AD) is the most common cause of dementia in older individuals (>65 years) and has a long presymptomatic phase. Preventive therapies for AD are not yet available, and potential disease-modifying therapies targeting amyloid-β plaques in symptomatic stages of AD have only just been approved in the United States. Small-molecule inhib...
Alternative Titles
Full title
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2575373709
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2575373709
Other Identifiers
ISSN
1759-4758
E-ISSN
1759-4766
DOI
10.1038/s41582-021-00545-1
